Lymphoma Hub

Por: Scientific Education Support

The Lymphoma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in lymphoma and CLL. Our aim is to enhance knowledge in lymphoma and CLL, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management. Hosted on Acast. See acast.com/privacy for more information.

53 episodios disponibles

Latest episodes of the podcast Lymphoma Hub

Symposium |Optimizing chronic lymphocytic leukemia management in a changing landscape 20/08/2026

Symposium | BTK inhibitors in practice: Treatment selection and emerging clinical evidence 12/08/2026

Symposium | BTK inhibitors in CLL: Mechanisms, clinical considerations, and unmet needs 12/08/2026

EHA 2026 | What are the key findings from the DALY 2-EU trial of zamto-cel in R/R LBCL? 21/07/2026

EHA2026 | What are the key findings from the subgroup analysis of the EPCORE FL-1 trial in R/R FL? 16/07/2026

Zanubrutinib for patients with previously untreated CLL/SLL: Insights from the SEQUOIA trial 10/07/2026

EHA 2026 | What are the key findings from the phase I ANTLER trial in R/R B-cell NHL? 01/07/2026

Annual oncology meeting | Key highlights in lymphoma 22/06/2026

EHA 2026 | What are the most recent findings from the phase I NX-5948-301 trial evaluating bexobrutideg in CLL?  17/06/2026

ASH 2025 | Key highlights in lymphoma and CLL 22/12/2025

ASH 2025 | Latest updates from the phase I NX-5948-301 trial of bexobrutideg in patients with R/R CLL 18/12/2025

What do the clinical data tell us about fixed-duration ibrutinib + venetoclax for patients with CLL? 17/12/2025

ASH 2025 | EPCORE FL-1 phase III primary results: Epcoritamab with rituximab + lenalidomide (R2) vs R2 alone for R/R FL 11/12/2025

ASH 2025 | 3-year follow-up results from the STARGLO trial of Glofit-GemOx vs R-GemOx in R/R DLBCL 10/12/2025

ASH 2025 | Epcoritamab for R/R DLBCL: Results from EPCORE NHL-6, by race and ethnicity 10/12/2025

Glofit-GemOx vs R-GemOx in patients with R/R DLBCL: Results from the STARGLO trial 05/12/2025

What factors influence BTKi + BCL-2i treatment selection for patients with CLL? 05/11/2025

Latest updates from the phase III STARGLO trial: 2L and 3L+ data 15/10/2025

Symposium | Customizing therapy for MCL: Q&A 04/09/2025

Symposium | Current therapies for MCL and their combinations 03/09/2025

1 2 3 Next Última »

Latest episodes

Lymphoma Hub

Latest episodes of the podcast Lymphoma Hub

Thank you

Active Podcasts